US DOJ Closes Investigation into Plato UNITED STATES

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 19, 2014 at 2:15 AM

US DOJ Closes Investigation into Plato

UNITED STATES DEPARTMENT OF JUSTICE CLOSES INVESTIGATION INTO PLATO CLINICAL TRIAL FOR BRILINTA AstraZeneca today announced that it has received confirmation from the United States Department of Justice that it is closing its investigation into PLATO, a clinical trial with Brilinta (ticagrelor). The government is not planning any further action. Pascal Soriot, Chief Executive Officer, said: "We welcome the Department of Justice's decision not to pursue further action. We have always had absolute confidence in the integrity of the PLATO trial and we are proud of the important benefit Brilinta offers to patients around the world suffering from acute coronary syndrome. As one of AstraZeneca's growth platforms, we are committed to delivering the full potential of this important medicine." AstraZeneca recently announced the start of the SOCRATES trial, studying Brilinta for patients with acute ischemic stroke or transient ischemic attack, and the THEMIS study in patients with Type 2 diabetes and coronary atherosclerosis. These studies form part of PARTHENON, AstraZeneca's largest ever clinical trial programme, involving more than 80,000 patients worldwide. The programme also includes two trials that have recently completed recruitment; EUCLID for patients with Peripheral Artery Disease and PEGASUS, studying Brilinta for secondary prevention in patients with previous myocardial infarction. Headline results for PEGASUS are expected in the first quarter of 2015. In 2011, the US Food and Drug Administration approved Brilinta for the treatment of patients with acute coronary syndrome (ACS). Brilinta has been approved by regulatory authorities in over 100 countries and is included in 11 major ACS treatment guidelines globally, including six established US treatment guidelines. The trial manuscript from the PLATO Executive Committee was first published in the New England Journal of Medicine. Following additional rigorous peer-review, over 30 PLATO sub-analyses articles have subsequently been published. The combination of these global reviews makes the PLATO data set one of the most widely analysed clinical trials. About the civil investigative demand On 21 October 2013, AstraZeneca received a civil investigative demand from the US Department of Justice seeking documents and information related to the PLATO trial. AstraZeneca has cooperated with the government enquiry, which focused on questions that have been raised previously in public about the trial. Similar questions have been responded to by the independent PLATO Executive Committee which led the clinical trial. About the PLATO trial PLATO was a large (18,624 patients in 43 countries), head-to-head patient outcomes study of BRILINTA vs. clopidogrel, both given in combination with aspirin and other standard therapy. The trial was designed to establish whether BRILINTA plus aspirin could achieve a clinically meaningful reduction in cardiovascular (CV) events in acute coronary syndrome (ACS) patients, above and beyond that afforded by clopidogrel plus aspirin. Patients were treated for at least 6 months and up to 12 months. BRILINTA plus aspirin has been proven clinically superior to clopidogrel plus aspirin, in reducing thrombotic CV events, including CV death, at 12 months, based on data from the PLATO trial. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com CONTACTS Media Enquiries Esra Erkal-Paler +44 20 7604 8030 (UK/Global) Vanessa Rhodes +44 20 7604 8037 (UK/Global) Ayesha Bharmal +44 20 7604 8034 (UK/Global) Jacob Lund +46 8 553 260 20 (Sweden) Michele Meixell + 1 302 885 6351 (US) Investor Enquiries Karl Hård +44 20 7604 8123 mob: +44 7789 654364 Jens Lindberg +44 20 7604 8414 mob: +44 7557 319729 Anthony Brown +44 20 7604 8067 mob: +44 7585 404943 Eugenia Litz +44 20 7604 8233 mob: +44 7884 735627 19 August 2014 -ENDS-

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kansas City Life Welcomes Kellie Needham to Board

A New Era in Kansas City Life's Leadership This ain't your run-of-the-mill board appointment, folks. Kansas City Life Insurance Company has just handed the reins to Kellie S. Needham, who steps in to fill her mother's recently vacated board seat. Imagine that—a family legacy stretching back to the early 1900s when J.B. Reynolds first laid the foundation. Legacy Unbroken...

Hehe Culture's Timeless Wisdom Explored at Forum

Hehe Forum: Bridging the Past and Present Sometimes, the past isn't just anchor weight, it's a compass guiding us through the murky waters of today. The Hehe Culture Forum's latest gathering in Tiantai County, Zhejiang Province, aimed to unravel just how much ancient wisdom can still steer the course in this fast-changing world. Delegates from 23 nations joined forces,...

Systemair Shakes Things Up: Closing Netherlands Facility

Systemair's Shocking Shutdown Decision Feels like we're strapped into a roller coaster with these HVAC companies lately. Systemair (NASDAQ Stockholm: SYSR) sure gave us quite the surprise ride by announcing they're pulling the plug on their production facility in Waalwijk, the Netherlands. This isn't just a ripple in a pond; it's a splash that might make some waves in the...

Are Shareholder Interests at Risk in These Deals?

Potential Pitfalls in Pending Transactions In the tangled world of corporate deals, not every handshake benefits everyone around the table. This time, it's Surgery Partners, Range Resources, and Penske Automotive Group finding themselves under legal scrutiny. We'll dig into why Nasdaqq:SGRY, Nyse:RRC, and Nyse:PAG, might have some explaining to do. Whose Pockets Are...

Barco Brings HDR Cinema Home with Kinepolis Kortrijk

A New Chapter in Cinema Projection Ah, Belgium, the land of waffles and apparently, cutting-edge cinema tech. That's right, Barco is bringing their HDR by Barco system to its own backyard in Kortrijk, teaming up with Kinepolis to shake things up. It's not just any expansion—it's a homecoming of sorts. The company's laser cinema magic has already made face time in the...

Food Emulsifiers Surge: Market to Hit $5.60B by 2031

Forecasting Growth in Food Emulsifiers Picture this: the food emulsifiers market is steaming ahead, anticipating a thunderous boom from $4.43 billion in 2026 to a whopping $5.60 billion by 2031. According to recent estimates, that's a steady clip at a CAGR of 4.8%. If you're thinking that's just more industry chatter, let's peel back the layers and see what makes this...

Landstar Faces Legal Storm Post Earnings Miss

Landstar's Earnings Misstep Sends Shockwaves Alright, let's talk about this snafu at Landstar (NASDAQ: LSTR). They were supposed to deliver an earnings sheet that's all roses, but instead, we got a couple of thorns. Analysts were expecting them to strike gold with EPS numbers between $1.62 to $1.67. What we got? A measly $1.42. Not exactly the shiny haul we were led to...

NeuroSense's Phase 3 Strategies for PrimeC Unveiled

How NeuroSense Is Poised to Tackle ALS Treatment Picture this: a room full of people holding their breath, hoping that NeuroSense can deliver the breakthrough they’ve been inching toward. It’s the kind of moment that gives you goosebumps if you've been sloggin' through the biotech trenches. NeuroSense’s pitch at NEALS is more than just a dog and pony show—it's a...

YSS Faces Legal Heat Over Misleading Investor Claims

YSS Investors Navigate Legal Waters as Class Action Looms Taking a slug of coffee this morning and diving right into it—York Space Systems has found itself in hot water. They went public earlier this year with what was supposed to be a shining opportunity under the NYSE:YSS ticker, but it turns out that not everything in their IPO shined—and now SBS Law is stepping up...

Why Haunted Attractions Keep Us Coming Back for Fear

Welcome to Fear Incarnated Ah, Kansas City. More than just jazz and barbeque. You’ve got these infamous haunted houses that turn every horror flick into a mere Saturday morning cartoon. Enter Edge of Hell and Beast Haunted Attraction. Two horrifying museums of fear that somehow lure us like flies to sugar from miles away. What's the secret sauce? Well, that’s half the...